A timeline of in vivo gene therapy. (IMAGE)
Caption
Progress of in vivo gene therapy for use in malignancies, monogenic disorders, and degeneration disease. AAV, adeno-associated virus; TK, thymidine kinase; ADA-SCID, adenosine deaminase-deficient severe combined immunodeficiency; AdV, adenovirus; OV, oncolytic virus; HSV, herpes simplex virus; NMIBC, non-muscle invasive bladder cancer; LCA, Leber’s congenital amaurosis; HA, hemophilia A; HB, hemophilia B; AADCd, aromatic l-amino acid decarboxylase deficiency; DEB, dystrophic epidermolysis bullosa; DMD, Duchenne muscular dystrophy.
Credit
Tao Wang, Mingyang Yu, Ping Liu, Zhiqiang Song, Cheng Li, Jianmin Yang, Na Liu
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND